Jeanne Lenzer, associate editor of the British Medical Journal, has published an investigative report showing how the U.S. Centers for Disease Control and Prevention (CDC) is not honest when publishing disclaimers in their studies stating that “they have no financial interests or other relationships with the manufacturers of commercial products.”
This news does not come as a surprise to those of us in the alternative media, but it is significant that the report was published in one the world’s most respected medical journals, the British Medical Journal. Lenzer explains why this is so significant:
The CDC’s image as an independent watchdog over the public health has given it enormous prestige, and its recommendations are occasionally enforced by law.
She goes on to quote Marcia Angell, former editor in chief of the New England Journal of Medicine:
The CDC has enormous credibility among physicians, in no small part because the agency is generally thought to be free of industry bias. Financial dealings with biopharmaceutical companies threaten that reputation.
CDC Receives Millions of Dollars in Industry Gifts and Funding
Lenzer goes on to document in her investigative report how the CDC has been receiving millions of dollars in “industry gifts and funding” since at least 1983.
Despite the agency’s disclaimer, the CDC does receive millions of dollars in industry gifts and funding, both directly and indirectly, and several recent CDC actions and recommendations have raised questions about the science it cites, the clinical guidelines it promotes, and the money it is taking.
Lenzer writes that in 1983 the CDC was “authorised” to accept this funding from pharmaceutical companies, and that in 1995 Congress actually passed legislation that was signed into law by President Bill Clinton “to encourage relationships between industry and the CDC.”
Jeanne Lenzer’s report in the BMJ gives several examples of how funding from the pharmaceutical industry probably effected the outcomes of research studies used to promote questionable drugs.
Whiles Lenzer’s report did not touch on the explosive topic of vaccines, we will remind our readers here of a few facts showing the obvious conflicts of interest within the CDC in overseeing vaccine safety, and setting vaccine policy.
The 2015 fiscal budget of the CDC is $6.6 billion, a decrease of $243 million from 2014. However, “Vaccines for Children” is the largest category within the budget, and it increased from $3.5 billion in 2014 to $4 billion in 2015, an increase of $514 million. So the American taxpayer, through the CDC, is forcibly purchasing $4 billion of vaccines from the pharmaceutical industry. (Source.)
Can we trust the CDC to give us accurate information regarding the efficacy and safety of vaccines?
Last year (2014) Dr. William Thompson of the CDC became a whistleblower and revealed that one of the key studies the CDC has used for years to make the claim that vaccines are safe and not linked to autism withheld key data that did not support their conclusion….
The mainstream media, with strong ties to the pharmaceutical industry themselves, basically ignored this story which should have been one of the top news stories of 2014.
Former CDC Director Julie Gerberding Becomes Head of Merck’s Vaccine Division
Julie Gerberding was in charge of the Centers for Disease Control and Prevention (CDC) from 2002 to 2009, which includes the years the FDA approved the Merck Gardasil vaccine. Soon after she took over the CDC, she reportedly completely overhauled the agency’s organizational structure, and many of the CDC’s senior scientists and leaders either left or announced plans to leave. Some have claimed that almost all of the replacements Julie Gerberding appointed had ties to the vaccine industry.
Gerberding resigned from the CDC on January 20, 2009, and took over as the president of Merck’s Vaccine division, a 5 billion dollar a year operation, and the supplier of the largest number of vaccines the CDC recommends (article here).
It was reported last month (May 2015) that Dr. Gerberding, now the executive vice president of pharmaceutical giant Merck, sold 38,368 of her shares in Merck stock for $2,340,064.32. She still holds 31,985 shares of the company’s stock, valued at about $2 million. (Source.)